AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mehta, S. P
Right arrow Articles by Rhodes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, S. P
Right arrow Articles by Rhodes, M.
Agricola
Right arrow Articles by Mehta, S. P
Right arrow Articles by Rhodes, M.
American Journal of Clinical Nutrition, Vol. 87, No. 4, 949-956, April 2008
© 2008 American Society for Nutrition


ORIGINAL RESEARCH COMMUNICATION

Effect of n–3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus 1,2,3

Samir P Mehta, Alex P Boddy, Jane Cook, Virginia Sams, Elizabeth K Lund, Ian T Johnson and Michael Rhodes

1 From the Department of Upper Gastrointestinal Surgery (SPM, APB, JC, and MR) and the Department of Histopathology (VS), Norfolk and Norwich University Hospital, Norwich, United Kingdom, and the Institute of Food Research, Norwich, United Kingdom (SPM, APB, EKL, and ITJ)

Background: Epidemiologic studies suggest a reduced risk of esophageal adenocarcinoma in populations with a high consumption of fish, and n–3 fatty acids inhibit experimental carcinogenesis. One possible explanation is the suppression of eicosanoid production through inhibition of cyclooxygenase 2 (COX-2).

Objective: The objective was to determine the effects of dietary supplementation with the n–3 fatty acid eicosapentaenoic acid (EPA) on a number of biological endpoints in Barrett's esophagus.

Design: Fifty-two participants with known Barrett's esophagus underwent endoscopy. Biopsy samples were obtained from a recorded level within the area of Barrett's esophagus, and then 27 patients were randomly assigned to consume EPA capsules (1.5 g/d) for 6 mo or no supplement (controls). At the end of this period, patients again underwent endoscopy, and biopsy samples were collected at the same level. Tissue samples were analyzed for mucosal lipid, prostaglandin E2, leukotriene B4, COX-2 protein, and RNA concentrations. Cellular proliferation was also measured, by Ki-67 immunohistochemistry.

Results: The EPA content of esophageal mucosa increased over the study period in the n–3–supplemented subjects and was significantly different from the content in the controls (P < 0.01). There was also a significant decline in COX-2 protein concentrations (measured by immunoblotting) in the n–3 group, and the difference was significant from that in the controls (P < 0.05); no difference in COX-2 RNA concentrations was observed between groups. This change in COX-2 protein was inversely related to the change in EPA content (P < 0.05). There was no significant difference in the change in prostaglandin E2, leukotriene B4, or cellular proliferation between the 2 groups.

Conclusion: Supplementation with EPA significantly changed n–3 fatty acid concentrations and reduced COX-2 concentrations in Barrett's tissue.




This article has been cited by other articles:


Home page
Toxicol Ind HealthHome page
P. Wertz
Essential fatty acids and dietary stress
Toxicology and Industrial Health, May 1, 2009; 25(4-5): 279 - 283.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The American Society for Nutrition